Scienmag

SEPTEMBER 18, 2020

Antibody-like proteins that capture and neutralize SARS-CoV-2 Scientists have used a new high-speed, in vitro selection method to isolate 9 antibody-like proteins (ALPs) that bind to the SARS-CoV-2 virus – 4 of which also exhibited neutralizing activity – within 4 days, according to a new study.

Protein 53

Protein Antibody In-Vitro Scientist 53

The Pharma Data

AUGUST 15, 2021

Even as several safe and effective COVID-19 vaccines are being administered to people worldwide, scientists are still hard at work developing different vaccine strategies that could provide even stronger or longer-lasting immunity against SARS-CoV-2 and its variants.

Protein 52

Protein Vaccination Vaccine Antibody 52

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

Antibody 64

Antibody Engineer Protein Scientist 64

XTalks

NOVEMBER 20, 2020

A new type of test based on detection of activated T cells may prove to have greater utility in determining whether someone has had a COVID-19 infection compared to a traditional antibody test. Researchers at Adaptive Biotechnologies compared T-Detect to a commercial antibody test from DiaSorin on samples obtained from people in Vo’, Italy.

Antibody 98

Antibody Immune Response Protein In-Vitro 98

XTalks

MARCH 11, 2021

Amidst initial confusion, fear and chaos, masks and social distancing quickly became new norms, and now vaccines are leading hope for a way out. As a novel virus, public health experts, scientists and clinicians faced challenges in how to effectively prevent its transmission, and how to best treat it in the most severe cases.

Vaccination 98

Vaccination Vaccine In-Vitro Antibody 98

Drug Discovery World

FEBRUARY 16, 2024

Seiler echoed these sentiments, particularly the evolution of cancer therapeutics in which we aim to target the cancer itself, and the turning point of about ten years ago where scientists began engaging the immune system for controlling homeostasis within individual tissues and organs.

Research 52

Research In-Vitro Drugs Vaccination 52

Drug Discovery World

FEBRUARY 15, 2023

These have been the most promising form of antibodies being developed, with Ipilimumab (CTLA4 blocking) and Nivolumab (PD1 blocking) now approved by the US Food and Drug Administration (FDA) for more than nine cancer types. Half of people diagnosed with cancer in England and Wales survive their disease for 10 years or more (2010-11) 1.

Research 52

Research In-Vitro In-Vivo Development 52